Cincera Therapeutics

Cincera Therapeutics is developing a novel drug class as a modern approach to the treatment of fibrotic diseases. Enabling reductions in fibrosis at far smaller doses than current benchmark compounds, Cincera’s therapies could have potentially life-saving impacts for sufferers of fibrosis and transform the treatment landscape of fibrotic diseases.

Year established: 2021
Lead Researcher & Founder: Bernie Flynn (Monash)
Lead researcher: Stuart Pitson (UniSA)
Website: cinceratx.com